Leases	9 Months Ended
Sep. 30, 2026
Leases [Abstract]
Leases	Leases The Company leases office and laboratory space under a non-cancelable operating lease. In addition, the Company subleases a portion of its office and laboratory space. In September 2025, the Company entered into a sublease agreement with a third party, or the 2025 Sublease, for a portion of the office and laboratory space in Suite 200 at 490 Arsenal Way, Watertown, Massachusetts. The term of the 2025 Sublease ends in January 2029, with an option to extend for an additional two-year term. The Company began recognizing sublease income upon the commencement of the 2025 Sublease in February 2026. The Company performed an impairment analysis, which resulted in the recognition of a $10.7 million impairment charge for the three and nine months ended September 30, 2025. The impairment charge reduced the carrying value of the associated right-of-use asset, leasehold improvements, and certain furniture and fixture assets that remained in the facility to their estimated fair values. The fair values were estimated using a discounted cash flows approach based on forecasted future cash flows expected to be derived from the property based on the then-current sublease market rent, which was considered a Level 3 input in the fair value hierarchy, and other key assumptions, such as future sublease market conditions and the discount rate. There have been no material changes to the terms of the Company’s lease during the nine months ended September 30, 2026.

The Company leases office and laboratory space under a non-cancelable operating lease. In addition, the Company subleases a portion of its office and laboratory space. In September 2025, the Company entered into a sublease agreement with a third party, or the 2025 Sublease, for a portion of the office and laboratory space in Suite 200 at 490 Arsenal Way, Watertown, Massachusetts. The term of the 2025 Sublease ends in January 2029, with an option to extend for an additional two-year term. The Company began recognizing sublease income upon the commencement of the 2025 Sublease in February 2026.

The Company performed an impairment analysis, which resulted in the recognition of a $10.7 million impairment charge for the three and nine months ended September 30, 2025. The impairment charge reduced the carrying value of the

associated right-of-use asset, leasehold improvements, and certain furniture and fixture assets that remained in the facility to their estimated fair values. The fair values were estimated using a discounted cash flows approach based on forecasted future cash flows expected to be derived from the property based on the then-current sublease market rent, which was considered a Level 3 input in the fair value hierarchy, and other key assumptions, such as future sublease market conditions and the discount rate.